

---

**NAME: Tiffany A. Traina, MD**  
**INSTITUTION: Memorial Sloan Kettering Cancer Center**  
**OPEN SEAT: Society Nominating Committee Undesignated Member**

---

**A. EDUCATION, POSTDOCTORAL TRAINING, LICENSURE & CERTIFICATION**

**Education:**

1999 M.D. Weil Cornell Medical College, New York, NY  
1994 B.S. Cornell University (Biology), New York, NY

**Postdoctoral Training:**

2004-2005 Chief Fellow, Memorial Sloan Kettering Cancer Center, New York, NY  
2003-2006 Fellow, Medical Oncology & Hematology, Memorial Sloan Kettering Cancer Center, New York, NY  
2003-2006 Fellow, Internal Medicine, New York Presbyterian Hospital | Cornell University, New York, NY  
2002-2003 Chief Resident, Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY  
2000-2002 Resident, Internal Medicine, New York Presbyterian Hospital | Cornell University, New York, NY  
1999-2000 Intern, Internal Medicine, New York Presbyterian Hospital | Cornell University, New York, NY

**Licensure and Certification:**

2020 New Jersey License  
2006 Hematology – Eligible certificate  
2006 Medical Oncology certificate  
2002 Internal Medicine certificate  
2000 New York License

---

**B. APPOINTMENTS**

**Academic Appointments**

2016- Associate Professor, Weill Cornell Medical College  
2015- Associate Member, Memorial Hospital, Memorial Sloan Kettering Cancer Center  
2013- Special Contributing Faculty Member, Gerstner Sloan Kettering Graduate School  
2010-2016 Assistant Professor, Weill Cornell Medical College  
2009-2015 Assistant Member, Memorial Sloan Kettering Cancer Center  
2007-2010 Instructor, Weill Cornell Medical College  
2006-2009 Assistant Member (Level I), Memorial Sloan Kettering Cancer Center

## Hospital Appointments:

|           |   |
|-----------|---|
| 2021-     | Co-Chair, Outpatient Operations Committee, Memorial Hospital for Cancer and Allied Diseases                     |
| 2021-     | Elected Officer, Medical Staff Advisory Council, Memorial Hospital for Cancer and Allied Diseases               |
| 2019-     | Vice Chair, Dept. of Medicine; Oncology Operations, Memorial Hospital for Cancer and Allied Diseases            |
| 2016-     | Section Head – Triple Negative Breast Cancer Research Program, Memorial Hospital for Cancer and Allied Diseases |
| 2016-2020 | Clinical Director, Breast Medicine Service, Memorial Hospital for Cancer and Allied Diseases                    |
| 2015-     | Associate Attending Physician, Memorial Hospital for Cancer and Allied Diseases                                 |
| 2006-2015 | Assistant Attending Physician, Memorial Hospital for Cancer and Allied Diseases                                 |

---

## C. PROFESSIONAL ORGANIZATIONS AND EDUCATIONAL CONTRIBUTIONS

### Professional Organizations:

|       |   |
|-------|---|
| 2003- | American Society of Clinical Oncology                   |
| 2006- | Translational Breast Cancer Research Consortium (TBCRC) |
| 2020- | American Association of Cancer Research                 |

### Educational Contributions:

#### *Select Recent Lectures*

|              |  |
|--------------|--|
| 2022         | Breast Medical Oncology Professor in Residence, MSK Open Medical Institute, Salzburg, Austria  |
| 2022         | Updates on Metastatic TNBC, Abu Dhabi  |
| 2020-ongoing | Annual Chemotherapy Foundation Symposium Co-Chair, New York, NY  |
| 2020-2022    | Annual Advances in Metastatic TNBC, Breast Cancer Symposium, Hudson, NY  |
| 2022         | Virtual educational program, TNBC and Disparities in Care  |
| 2022         | ASCO Direct Highlights 2022, New York City   |
| 2020-2022    | Triple Negative Breast Cancer, Pink and Teal Conference, Bermuda   |
| 2022         | Standards of Care in Management of TNBC, MSK International Center lecture, China   |
| 2022         | TNBC, Miami Breast Conference, Miami, FL   |
| 2019-2021    | Metastatic Breast Cancer Principles, School of Breast Oncology, Atlanta, GA  |
| 2021         | MSK Alliance Miami Baptist Hospital Grand Rounds: Management of Metaplastic TNBC   |
| 2019         | MSK Alliance Miami Baptist Hospital Grand Rounds: Advances in the Management of Metastatic TNBC, MSK Alliance Miami Baptist Hospital Physician |
| 2019-2021    | Norwalk Hospital Tumor Board,  |
| 2019-2021    | Updates in the management of MBC, Invited guest lecturer, India  |
| 2021         | Virtual, ASCO Direct Highlights, Philadelphia, PA  |
| 2021         | Standards of Care in Management of TNBC, MSK International Center lecture, Ireland   |
| 2021         | NBCC, Updates on the management of TNBC and Gene sequencing in metastatic breast cancer, virtual presentations                                 |
| 2021         | Invited lecture, COVID and Cancer, Virtual AACR presentation   |
| 2020         | Spotlight Session Discussant in HER2+ Breast Cancer, San Antonio Breast Cancer Symposium   |
| 2019         | The Concept of Immunotherapy and Immunotherapy in Breast Cancer, MPANGO Conference, Kenya  |
| 2019-        | MSK Alliance SABCS TNBC Highlights, MSK Alliance   |
| 2015-        | Department of Medicine Grand Rounds ASCO Highlights Breast Oncology, MSKCC Physicians  |

*Clinical teaching (bedside teaching, teaching rounds, teaching in operating room, precepting in clinic, morning report, etc.)*

2022-2016- Clinical mentor for City University of NY medical student, weekly  
Medicine; Patients & Society (1 day/week) Clinical Preceptor, Weill Cornell Medical College Students

2015- LEAP MSKCC Liaison, Weill Cornell Medical College Students  
2015- LEAP Faculty Preceptor, Weill Cornell Medical College Students  
2010- Weill Cornell Medical College Students "Essential Principals of Medicine," Weill Cornell Medical College Students

2006- MSKCC Medical Oncology Fellows Clinic Tues/Thurs, MSK Fellows  
2006- MSK Pharmacy students in clinic

*Administrative teaching (leadership role as residency or fellowship director, course director)*

2017-2019 Course Director, Department of Medicine Ground Rounds, MSK Physicians

---

## **D. AWARDS, HONORS, CLINICAL PRACTICE AND LEADERSHIP**

### **Awards:**

2021 Nominated for position on Nomination Committee in ASCO 2022 election, American Society of Clinical Oncology

2020 MSK Physician Executive Development Program; Invitation only, year-long, Executive and Leadership program, MSK

2018 Named to Forbes' List of Top Breast Cancer Oncologists, Forbes

2018-2024 Appointed to highly competitive President's Council of Cornell Women (6 year term), Cornell University

2016-2017 Awarded Competitive Acceptance to the ASCO Leadership Development Program, American Society of Clinical Oncology

2015 Excellence in Teaching Award, Weill Cornell Medical College

2015 MSK 11th Annual Quality and Performance Improvement Fair for project Improved Access and Planning for Neoadjuvant Breast Cancer Referrals, MSKCC

2015 Awarded Competitive Acceptance to the ASCO Leadership Skills Workshop, American Society of Clinical Oncology

2015 Awarded Competitive Acceptance to the AAMC Executive Development Seminar for Interim and Aspiring Leaders, AAMC

2014 PLC 2014 Hero Award, Triple Negative Breast Cancer Foundation

2013 Department of Medicine Housestaff Teaching Certificate of Appreciation, MSKCC

2012 Department of Medicine Housestaff Teaching Certificate of Appreciation, MSKCC

2011 Awarded Competitive Admission to the American Association of Medical Colleges (AAMC) Early Career Women Faculty Professional Development Seminar, AAMC

2011-2012 Outstanding Service Award, Junior League of Stamford-Norwalk

2010 Hally Yacino Steiner Award for Triple Negative Breast Cancer, Susan G. Komen for the Cure, Greater New York City Affiliate

2007 Donald W. Reynolds FD-AGE Mini Fellowship at University of California, LA, University of California

2005-2006 National Comprehensive Cancer Center Network (NCCN) Fellows Recognition Program, NCCN

2005 American Society of Clinical Oncology (ASCO) Travel Grant, ASCO

2004 Awarded Competitive Acceptance to AACR-ASCO Workshop for Methods in Clinical Cancer Research, ASCO/AACR

1997-1998 Class of 1969 Scholarship, Weill Cornell Medical College

1992-1993 Dean's List, Cornell University, College of Agriculture and Life Sciences

### **Clinical Practice, Innovation and Leadership**

*Clinical Practice*

- 2006- Breast Medicine Service Inpatient Rounds Attending Care for breast cancer patients who require hospitalization to manage complications of breast cancer or its therapy / BAIC
- 2006- Breast Medicine Service Chemotherapy attending at MSK Breast and Imaging Center Respond to emergencies and address clinical questions about patients that arise during the administration of chemotherapy at BAIC / BAIC
- 2006- Breast Medicine Service MSK Outpatient Clinic Attending Care of outpatients with both early-stage and metastatic breast cancer, managing chemotherapy, endocrine therapy, and antibody therapy. Special interest in treatment of patients with triple negative breast cancer BAIC

*Clinical Innovations*

- 2021 Physician Lead, Navya Pilot for MSKDirect Remote Opinions and External Consultation, Pilot and Implementation of AI- Assisted Clinical Summary Creation for External NV
- 2021 Lead, Pilots of EPACS in Department of Medicine, Facilitating Care Coordination Through RN or APP Outreach to External NV Consultations Prior to Initial Visit

*Clinical Leadership*

- 2016-2020 Clinical Director, Breast Medicine Service, Manage clinical operations of more than 40 Breast Medicine faculty across all ambulatory care locations at MSK.

**Institutional Responsibilities:**

*Mentoring*

- 2015- Weill Cornell Medical College: Internal Medicine Interest Group Faculty Mentor
- 2014-2019 Weill Cornell Medical College Oncology Interest Group Founding faculty member
- 2014-2019 Weill Cornell Medical College Alumni-to-Student (ASK) Program Panel Member on Internal Medicine and Subspecialties
- 2014 Weill Cornell Medical College Women in Medicine Chapter & Weill Cornell Medical College Faculty Mentor Panel member; Work Life Balance
- 2010- Weill Cornell Medical College Program for Women Faculty Affairs/Junior Faculty Development Mentor

*Institutional Leadership Activities*

- 2021- Medical Staff Council – Elected Office, Memorial Hospital for Cancer and Allied Diseases
- 2021- MSK Height/Weight Clinical Standard Interprofessional Working Group, MSKCC
- 2021- Co-Chair, Outpatient Operations Committee, Memorial Hospital for Cancer and Allied Diseases
- 2020- MSKCC COVID Resurgence Planning, Outpatient Lead, Memorial Sloan Kettering Cancer Center
- 2020- MSKCC COVID Outpatient Restoration, Lead, Memorial Sloan Kettering Cancer Center
- 2019- Vice Chair, Dept. of Medicine; Oncology Operations, Memorial Hospital for Cancer and Allied Diseases
- 2016-2020 Clinical Director Breast Medicine Service, Memorial Hospital for Cancer and Allied Diseases
- 2015- Section Head – Triple Negative Breast Cancer Research Program, Memorial Hospital for Cancer and Allied Diseases

*Institutional Administrative Activities*

- 2022- Member, MSKCC Search Committee for Chief, Cardiology Service
- 2021 Member, MSKCC Search Committee for Division Head for Acute and Supportive Care Services
- 2018- Member, MSKCC Clinical Competency Committee
- 2017-2019 Member, MSKCC Course Director, Department of Medicine Grand Rounds
- 2017-2019 Member, MSKCC End of Life Root Cause Working Group
- 2016-2020 Member, MSKCC Research Council
- 2016-2018 Member, MSKCC Search Committee Member: Chief, Breast Medicine Service
- 2015- Member, MSKCC Clinical Genomics Annotation Committee (CGAC)
- 2014 Member, MSKCC Search Committee Member: Chair Radiology, West Harrison

|           |   |
|-----------|---|
| 2014-2020 | Member, MSKCC Alliance – Breast Medicine liaison              |
| 2013-2016 | Member, MSKCC Data Safety Monitoring Committee                |
| 2012-     | Member, MSKCC Breast Cancer DMT Triple Negative Working Group |
| 2012-     | Member, MSKCC Department of Medicine QA Committee             |
| 2009      | Member, MSK Telemedicine Initiative                           |
| 2008      | Member, MSK Survivorship Planning Committee                   |
| 2007-2009 | Member, MSK Junior Faculty Peer Advisory Group                |
| 2007-2009 | Member, MSK Junior Faculty Committee Member                   |
| 2007-     | Member, MSK Comskill Laboratory Facilitator                   |
| 2006-2009 | Member, MSK Geriatrics Team                                   |
| 2005-2006 | Member, MSK Department of Medicine QA Committee               |
| 2002-2003 | Member, MSK Department of Medicine QA Committee               |

## **Extramural Professional Responsibilities:**

### *Leadership in Extramural Organizations*

|           |  |
|-----------|--|
| 2022      | ASCO Election Candidate  |
| 2020-     | Member and Co-Chair, ASCO Breast Cancer Guideline Advisory Group |
| 2017-2021 | Member and Past Chair, ASCO Membership Committee                 |
| 2020-     | Co-Chair, Chemotherapy Foundation Symposium                      |

### *National*

|           |   |
|-----------|---|
| 2022-2025 | Member, ASCO Joint Certifications Committee, American Society of Clinical Oncology  |
| 2022      | Member, Breast Cancer Guideline Advisory Group (GAG), American Society of Clinical Oncology   |
| 2021      | Member, Nominating Committee – Chair of Latin America Regional Council, American Society of Clinical Oncology                               |
| 2020-2021 | Member, Road to Recovery Task Force, American Society of Clinical Oncology  |
| 2020-     | Member, ADCC Supportive Care Committee, Alliance of Dedicated Cancer Centers (ADCC) Improving Goals of Care Communication (IGCC) initiative |
| 2019-     | Member, Ayala AL101 Steering Committee  |
| 2018-2020 | Member, Membership Model Task Force, American Society of Clinical Oncology  |
| 2018      | Member, Autologous Breast Reconstruction Guideline Panel, American Society of Clinical Oncology   |
| 2017-2021 | Member, Membership Committee, American Society of Clinical Oncology   |
| 2016      | Member, Molecular Oncology Tumor Board, American Society of Clinical Oncology   |
| 2015-     | Member, BIG/Alliance “OlympiA” trial – Steering Committee, Global Clinical Trial Steering Committee Membership                              |
| 2015-     | MSKCC Site-PI, Translational Breast Cancer Research Consortium (TBCRC)  |
| 2014-     | Member, Educational Book – Breast Cancer Chapter Co-author and Editorial Panel, American Society of Clinical Oncology                       |
| 2014-2016 | Member, Scientific Program Committee Breast Cancer (TNBC/Cytotoxics/Loc Track), American Society of Clinical Oncology                       |
| 2013-2015 | Member, Global Clinical Trial Steering Committee Membership, Eisai  |
| 2010-     | Member, IMMU132 Steering Committee  |
| 2008-     | Member, I-SPY Trial, I-SPY Data and Safety Monitoring Board   |
| 2008-2020 | Member, Innocrin Seviterenol Breast Cancer Steering Committee   |
| 2008-2015 | Member, Neoadjuvant and Adjuvant Therapy Working Group, Translational Breast Cancer Research Consortium (TBCRC)                             |
| 2008      | Reviewer, Reviewer of institutional audits, Alliance (formerly CALGB)   |
| 2007      | Member, Breast Cancer in Older Woman Task Force, NCCN   |
| 2007-2008 | Member, Geriatric Oncology Planning Subcommittee, American Society of Clinical Oncology   |

### *International*

|       |   |
|-------|---|
| 2022- | Member, Scientific Advisory Board, Kembi Therapeutics                                 |
| 2021- | Member, TROPION-2 Steering Committee Global Trial in TNBC                             |
| 2021- | Alliance Representative, OlympiA Steering Committee, Breast International Group (BIG) |
| 2018- | Member, Steering Committee -- PALLAS trial  |
| 2018- | Steering Committee Member, Ayala AL101 Steering Committee                             |

### Grant Reviewing/Study Sections

2018- Reviewer, AACR Breast Cancer Grant Reviewer  
2014- Member External Grant Review Committee, Breast Cancer Alliance

### Recent, Select Invited And/Or Peer-Selected Presentations

2022 Breast Medical Oncology Professor in Residence, MSK Open Medical Institute, Salzburg, Austria  
2022 Updates on Metastatic TNBC, Abu Dhabi  
2020-ongoing Annual Chemotherapy Foundation Symposium Co-Chair, New York, NY  
2020-2022 Annual Advances in Metastatic TNBC, Breast Cancer Symposium, Hudson, NY  
2022 Virtual educational program, TNBC and Disparities in Care  
2022 ASCO Direct Highlights 2022, New York City  
2020-2022 Triple Negative Breast Cancer, Pink and Teal Conference, Bermuda  
2022 Standards of Care in Management of TNBC, MSK International Center lecture, China  
2022 TNBC, Miami Breast Conference, Miami, FL  
2019-2021 Metastatic Breast Cancer Principles, School of Breast Oncology, Atlanta, GA  
2021 MSK Alliance Miami Baptist Hospital Grand Rounds: Management of Metaplastic TNBC  
2019 MSK Alliance Miami Baptist Hospital Grand Rounds: Advances in the Management of Metastatic TNBC, MSK Alliance Miami Baptist Hospital Physician  
2019-2021 Norwalk Hospital Tumor Board,  
2019-2021 Updates in the management of MBC, Invited guest lecturer, India  
2021 Virtual, ASCO Direct Highlights, Philadelphia, PA  
2021 Standards of Care in Management of TNBC, MSK International Center lecture, Ireland  
2021 NBCC, Updates on the management of TNBC and Gene sequencing in metastatic breast cancer, virtual presentations  
2021 Invited lecture, COVID and Cancer, Virtual AACR presentation  
2020 Spotlight Session Discussant in HER2+ Breast Cancer, San Antonio Breast Cancer Symposium  
2019 The Concept of Immunotherapy and Immunotherapy in Breast Cancer, MPANGO Conference, Kenya  
2019- MSK Alliance SABCS TNBC Highlights, MSK Alliance  
2015- Department of Medicine Grand Rounds ASCO Highlights Breast Oncology, MSKCC Physicians

---

### E. BIBLIOGRAPHY

#### Select Recent Publications:

1. Wang DG, Barrios DM, Blinder VS, Bromberg JF, Drullinsky PR, Funt SA, Jhaveri KL, Lake DE, Lyons T, Modi S, Razavi P, Sidel M, Traina TA, Vahdat LT, Lacouture ME. Dermatologic adverse events related to the PI3K? inhibitor alpelisib (BYL719) in patients with breast cancer. *Breast Cancer Research and Treatment*. 2020, Aug;183:227-237. PMID:PMC7398571
2. Hoda RS, Brogi E, Dos Anjos CH, Grabenstetter A, Ventura K, Patil S, Selenica P, Weigelt B, Reis-Filho JS, Traina T, Robson M, Norton L, Wen HY. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. *Modern Pathology*. 2020, Nov;33:2221-2232. PMID:PMC8234788
3. Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg L, Chan S, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau M, Markova D, Tarazi J, Zhu Z, O'Brien T, Kelly CM, Winer E, Yardley DA. A randomized placebo controlled phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer. *Clinical Cancer Research*. 2020, Dec;26:6149-6157.
4. Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerria M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicentre, open-label, randomised, phase 3 study. *Lancet Oncology*. 2021, Feb;22:212-222.

5. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortels J, O'Shaughnessy J, Dieïras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, for the ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. *New England Journal of Medicine*. 2021, Apr;384:1529-1541.
6. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *New Engl J Med*. 2021, Jun
7. Ahles TA, Schofield E, Li Y, Ryan E, Root JC, Patel SK, McNeal K, Gaynor A, Tan H, Katheria V, Vazquez J, cognitive functioning and frailty in older breast cancer survivors. *J Geriatr Oncol*. 2021, Aug Traina T , Hurria A.. Relationship between
8. Gaynor AM, Ahles TA, Ryan E, Schofield E, Li Y, Patel SK, McNeal K, Traina T, Root JC.. Initial encoding deficits with intact memory retention in older long-term breast cancer survivors. *J Cancer Surviv*. 2021, Aug
9. Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Dieïras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. *Annals of Oncology*. 2021, Sep;32:1148-1156.
10. Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW. RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer. *Clinical Cancer Research*. 2021, Sep;27:4883-4897. PMID:PMC8416935
11. Grabenstetter A, Jungbluth AA, Frosina D, Hoda R, Dos Anjos CH, Patil S, Sevilimedu V, Weigelt B, Reis-Filho JS, Zhang H, Traina T, Robson ME, Brogi E, Wen HY. PD-L1 expression in metaplastic breast carcinoma using the PD-L1 SP142 assay and concordance among PD-L1 immunohistochemical assays. *American Journal of Surgical Pathology*. 2021, Sep;45:1274-1281.
12. Pennell NA, Dillmon M, Levit LA, Moushey EA, Alva AS, Blau S, Cannon TL, Dickson NR, Diehn M, Gonen M, Gonzalez MM, Hensold JO, Hinyard LJ, King T, Lindsey SC, Magnuson A, Marron J, McAneny BL, McDonnell TM, Mileham KF, Nasso SF, Nowakowski GS, Oettel KR, Patel MI, Patt DA, Perlmutter J, Pickard TA, Rodriguez G, Rosenberg AR, Russo B, Szczepanek C, Smith CB, Srivastava P, Teplinsky E, Thota R, Traina TA, Zon R, Bourbeau B, Bruinooge SS, Foster S, Grubbs S, Hagerty K, Hurley P, Kamin D, Phillips J, Schenkel C, Schilsky RL, Burris H. American Society of Clinical Oncology Road to Recovery report: Learning from the COVID-19 experience to improve clinical research and cancer care. *Journal of Clinical Oncology*. 2021, Jan;39:155-169.
13. Ahles TA, Schofield E, Li Y, Ryan E, Root JC, Patel SK, McNeal K, Gaynor A, Tan H, Katheria V, Vazquez J, Traina T, Hurria A. Relationship between cognitive functioning and frailty in older breast cancer survivors. *Journal of Geriatric Oncology*. 2022, Jan;13:27-32.
14. Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Lorenzo JJP, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Filho OM, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele A. Treatment exposure and discontinuation in the PALbociclib Collaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2negative early breast cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). *Journal of Clinical Oncology*. 2022, Feb;40:449-458.
15. Ferguson DC, Mata DA, Tay, T. KY., Traina TA, Gucalp A, Chandarlapaty S, D'Alfonso TM, Brogi E, Mullaney K, Ladanyi M, Arcila ME, Benayed R, Ross DS. Androgen receptor splice variant-7 in breast cancer: Clinical and pathologic correlations. *Modern Pathology*. 2022, Mar;35:396402. PMID:PMC8863633
16. Ahles TA, Orlow I, Schofield E, Li Y, Ryan E, Root JC, Patel SK, McNeal K, Gaynor A, Tan H, Katheria V, Vazquez J, Corrales-Guerrero S, Sadeghi K, Traina T, Hurria A. J The impact of APOE and smoking history on cognitive function in older, long-term breast cancer survivors. *Cancer Surviv*. 2022 Oct 24. doi: 10.1007/s11764-022-01267-z. Online ahead of print. PMID: 36279076
17. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delalogue S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓP, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppi G, Park YH, Yerushalmi R,

- Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. *Ann Oncol.* 2022 Oct 10;S0923-7534(22)04165-5. doi: 10.1016/j.annonc.2022.09.159. Online ahead of print. PMID: 36228963
18. Prakash R, Rawal Y, Sullivan MR, Grundy MK, Bret H, Mihalevic MJ, Rein HL, Baird JM, Darrah K, Zhang F, Wang R, Traina TA, Radke MR, Kaufmann SH, Swisher EM, Guérois R, Modesti M, Sung P, Jasim M, Bernstein KA. Homologous recombination-deficient mutation cluster in tumor suppressor *RAD51C* identified by comprehensive analysis of cancer variants. *Proc Natl Acad Sci U S A.* 2022 Sep 20;119(38):e2202727119. doi: 10.1073/pnas.2202727119. Epub 2022 Sep 13. PMID: 36099300
  19. Walsh EM, Gucalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, Troso-Sandoval T, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco PA, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA. Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study. *Breast Cancer Res Treat.* 2022 Oct;195(3):341-351. doi: 10.1007/s10549-022-06669-2. Epub 2022 Aug 20. PMID: 35986801
  20. Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee GM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, Mucci LA, Wibmer AG, Schultz N, Kantoff PW The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. *Clin Cancer Res.* 2022 Aug 15;28(16):3603-3617. doi: 10.1158/1078-0432.CCR-21-4272. PMID: 35670774
  21. O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. *Breast Cancer Res Treat.* 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. PMID: 35545724 Free PMC article. Clinical Trial.
  22. Mayer EL, Fesl C, Hlauseck D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele A Treatment Exposure and Discontinuation in the PALbociclib Collaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). *J Clin Oncol.* 2022 Feb 10;40(5):449-458. doi: 10.1200/JCO.21.01918. Epub 2022 Jan 7. PMID: 34995105 Clinical Trial.
  23. Ahles TA, Schofield E, Li Y, Ryan E, Root JC, Patel SK, McNeal K, Gaynor A, Tan H, Katheria V, Vazquez J, Traina T, Hurria A. Relationship between cognitive functioning and frailty in older breast cancer survivors. *J Geriatr Oncol.* 2022 Jan;13(1):27-32. doi: 10.1016/j.jgo.2021.07.011. Epub 2021 Aug 5. PMID: 34366276 Free PMC article.
  24. Gaynor AM, Ahles TA, Ryan E, Schofield E, Li Y, Patel SK, McNeal K, Traina T, Root JC. Initial encoding deficits with intact memory retention in older long-term breast cancer survivors. *J Cancer Surviv.* 2022 Oct;16(5):940-947. doi: 10.1007/s11764-021-01086-8. Epub 2021 Aug 6. PMID: 34357556